Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 10, Issue 4, 2015, Pages 603-610

  Tseng, Jeng Sen ^a,b   Yang, Tsung Ying ^b,c   Tsai, Chi Ren ^a,b   Chen, Kun Chieh ^a,b   Hsu, Kuo Hsuan ^a,b   Tsai, Meen Hsin ^a,d   Yu, Sung Liang ^e,f   Su, Kang Yi ^e,g   Chen, Jeremy J W ^a   Chang, Gee Chen ^a,b,c  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Epidermal growth factor receptor mutations; Lung adenocarcinoma; Peptide nucleic acid zip nucleic acid polymerase chain reaction clamp; plasma cell free DNA

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEPTIDE NUCLEIC ACID; PROTEIN TYROSINE KINASE INHIBITOR; ANILIDE; EGFR PROTEIN, HUMAN; EGFR TYROSINE KINASE INHIBITOR 324674; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL FREE SYSTEM; CLAMP; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; SURVIVAL RATE; TAIWAN; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANILIDES; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TAIWAN; YOUNG ADULT;

EID: 84938289394     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000443     Document Type: Article

References (35)

1. Shi Y, Au JS, Thongprasert S, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014 9 154 162
2. Lee CK, Brown C, Gralla RJ, Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-Analysis. J Natl Cancer Inst 2013 105 595 605
3. Thongprasert S, Duffield E, Saijo N, Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 2011 6 1872 1880
4. Leighl NB, Treatment paradigms for patients with metastatic non-small-cell lung cancer: First-, second-, and third-line. Curr Oncol 2012 19 S52 S58
5. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF, Management of non-small-cell lung cancer: Recent developments. Lancet 2013 382 709 719
6. Lindeman NI, Cagle PT, Beasley MB, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013 8 823 859
7. Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J, Tissue sampling in lung cancer: A review in light of the MERIT experience. Lung Cancer 2011 74 1 6
8. Eberhard DA, Giaccone G, Johnson BE, Non-Small-Cell Lung Cancer Working Group Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for use in the clinical trial setting. J Clin Oncol 2008 26 983 994
9. Sozzi G, Conte D, Leon M, Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003 21 3902 3908
10. Jahr S, Hentze H, Englisch S, DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001 61 1659 1665
11. Moreau V, Voirin E, Paris C, Zip Nucleic Acids: New high affinity oligonucleotides as potent primers for PCR and reverse transcription. Nucleic Acids Res 2009 37 e130
12. Paris C, Moreau V, Deglane G, Voirin E, Erbacher P, Lenne-Samuel N, Zip nucleic acids are potent hydrolysis probes for quantitative PCR. Nucleic Acids Res 2010 38 e95
13. Li Z, Zhang Y, Bao W, Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: A meta-Analysis. Targ Oncol 2014 9 381 388
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, AJCC Cancer Staging Handbook 2009 7th ed New York Springer
15. Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009 45 228 247
16. Nagai Y, Miyazawa H, Huqun, Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005 65 7276 7282
17. Brevet M, Johnson ML, Azzoli CG, Ladanyi M, Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011 73 96 102
18. Goto K, Ichinose Y, Ohe Y, Epidermal growth factor receptor mutation status in circulating free DNA in serum: From IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012 7 115 121
19. Kimura H, Kasahara K, Shibata K, EGFR mutation of tumor and serum in gefitinib-Treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006 1 260 267
20. Rosell R, Moran T, Queralt C, Spanish Lung Cancer Group Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009 361 958 967
21. Vallée A, Marcq M, Bizieux A, Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 2013 82 373 374
22. Marcq M, Vallée A, Bizieux A, Denis MG, Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-Time monitoring of therapeutic response to tyrosine kinase inhibitors? J Thorac Oncol 2014 9 e49 e50
23. Murtaza M, Dawson SJ, Tsui DW, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013 497 108 112
24. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009 15 2076 2084
25. Couraud S, Vaca Paniagua F, Villar S, Non-invasive diagnosis of actionable mutations by deep sequencing of circulating-free DNA in non-small cell lung cancer: Findings from BioCAST / IFCT-1002. Clin Cancer Res 2014 20 4613 4624
26. Nakamura T, Sueoka-Aragane N, Iwanaga K, Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol 2012 7 1369 1381
27. Zhao X, Han RB, Zhao J, Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013 85 119 125
28. Bai H, Mao L, Wang HS, Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009 27 2653 2659
29. Kimura H, Suminoe M, Kasahara K, Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007 97 778 784
30. Oxnard GR, Paweletz CP, Kuang Y, Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014 20 1698 1705
31. Jackman DM, Yeap BY, Sequist LV, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006 12 3908 3914
32. Mitsudomi T, Kosaka T, Endoh H, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005 23 2513 2520
33. Kawaguchi T, Takada M, Kubo A, Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010 5 620 630
34. Pirker R, Pereira JR, Szczesna A, Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer 2012 77 376 382
35. Kamalakaran S, Varadan V, Janevski A, Translating next generation sequencing to practice: Opportunities and necessary steps. Mol Oncol 2013 7 743 755